FY20 MRP meeting support
Ended Awarded Last action
- Contract number
- W81XWH20F0053
- Awardee
-
Leidos, Inc. UEI QLNMVC12KWY3 Part of Leidos Holdings, Inc.
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $155,757
Award facts
- Opportunity
-
- W81XWH17R0036 Solicitation number
- Meeting, Scientific and Administrative Support Services (MSASS), Request for Proposal (RFP) Award Notice · Posted Apr 12, 2017
- Meeting, Scientific and Administrative Support Services Award Notice · Posted Mar 22, 2017
- Contract value 87% obligated
- $179,451.68 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541690 Other Scientific and Technical Consulting Services
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Two Step
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$5,122 | |
| Supplemental Agreement for work within scope | -$12,000 | |
| Supplemental Agreement for work within scope | $15,825 | |
| Funding Only Action | $3,470 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $153,584 |
About this award
Leidos, Inc. was awarded a $179,451.68 delivery order contract by the Defense Health Agency's Medical Command to provide Melanoma Research Program meeting support through January 5, 2021. This cost-plus-fixed-fee contract supports research initiatives addressing the growing prevalence of melanoma diagnoses among active duty service members and veterans, where melanoma ranks as the fifth most common cancer among the veteran population. The work will be performed in Frederick, Maryland, with no small business set-aside designation applied to this award.
This delivery order represents Leidos' continued engagement in medical research support services across the Defense Health Agency, consistent with the company's broader portfolio of contracts supporting clinical research programs on conditions including cancer, traumatic brain injury, and rare diseases. The contract leverages Leidos' existing capabilities and infrastructure to coordinate and facilitate research meetings that advance the understanding and management of melanoma within the military health system.
Quick answers
Who was awarded contract W81XWH20F0053?
W81XWH20F0053 was awarded to Leidos, Inc. by Medical Command (Department of the Army) on February 5, 2020.
How much is contract W81XWH20F0053 worth?
The government has obligated $155,757 on W81XWH20F0053. Its current value, with exercised options, is $179,452.
Is contract W81XWH20F0053 an order under another contract?
Yes. W81XWH20F0053 is a delivery order under W81XWH17D0025, an indefinite delivery contract.
Was contract W81XWH20F0053 competed?
The extent of competition for W81XWH20F0053 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award